With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

Targeted therapies for high-risk leukemia in children have yet to be developed, but scientists at Université de Montréal and its affiliated Institute for Research in Immunology and Cancer are working ...

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation and a part of Danaher Corporation, has ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set ...

An international team of researchers led by the University of California San Diego has developed a new strategy to enhance pharmaceutical production in Chinese hamster ovary (CHO) cells, which are ...

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AbSci (ABSI – Research Report) and keeping the price target at ...